Are Wall Street Analysts Bullish on Medtronic Stock?

Its headquarters is located in Galway, Ireland, Medrtonic PLC (MDT), and it manufactures and sells devices -based medical treatments. A maximum of about $ 115 billion, the company derives revenues from four basic sectors: cardiovascular wallet, medical surgery wallet, neuroscience, and diabetes.

The MDT stock increased by 10.6 % over the past year, late behind the S&P 500 ($ SPX), which increased by 21.1 % during the same period. However, throughout the year, the MDT share is offered by 11.9 %, which exceeded the S&P 500 by 7.9 %.

Focusing on the industry, the MDT exceeded the decrease of the S&P Healthcare Equipment (XHE) by 8.3 % over the past year and a decrease of 13.3 % of the year.

On July 21, MedTronic announced that it had obtained the approval of CE Mark on the 780 grams of insulin connection system. The market initially responded with caution, but by the upcoming trading session, the shares increased by approximately 2.2 %.

For the current year, which ends in April 2026, analysts expect MDT to achieve 1.1 % EPS growth, reaching $ 5.55 on a reduced basis. It is worth noting that Medrtonic has been constantly overcome by unanimity estimates over the past four quarters.

Of the 30 analysts covering the MDT shares, the consensus classification is a “moderate purchase”, and it consists of 13 “strong” purchase, one “moderate purchase”, 15 “, and one” strong sale “.

The current analysts’ feelings are just up two months ago, when the MDT had a total of 12 rating “strong purchase”.

On July 16, Anthony Petron did Mizuho Financial Group, Inc. He believes that medtonic is in a good position in the medical technology sector.

Likewise, on July 15, Morgan Stanley (MS) collided with its target price from $ 98 to $ 107, reaffirming the “weight gain” classification. The company sees the continuous relative stability in the volumes of procedures and trends of capital spending through hospitals as a reason to stay based on industry, and on MedTronic in particular.

The average target price of $ 95.83 represents a 7.2 % installment for the current MDT price levels. Meanwhile, the high price goal in the street of $ 110 indicates a potential increase of 23.1 %.

On the date of publication, Kritika Sarmah did not have positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are only for media purposes. This article was originally published on Barchart.com